RU95122077A - NEW DERIVATIVE BISOXADIAZOLIDINE - Google Patents
NEW DERIVATIVE BISOXADIAZOLIDINEInfo
- Publication number
- RU95122077A RU95122077A RU95122077/04A RU95122077A RU95122077A RU 95122077 A RU95122077 A RU 95122077A RU 95122077/04 A RU95122077/04 A RU 95122077/04A RU 95122077 A RU95122077 A RU 95122077A RU 95122077 A RU95122077 A RU 95122077A
- Authority
- RU
- Russia
- Prior art keywords
- group
- formula
- substituted
- lower alkyl
- represented
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 7
- 125000004450 alkenylene group Chemical group 0.000 claims 6
- 125000002947 alkylene group Chemical group 0.000 claims 6
- 229910052717 sulfur Inorganic materials 0.000 claims 6
- 125000004434 sulfur atoms Chemical group 0.000 claims 6
- -1 pyridinediyl group Chemical group 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000011780 sodium chloride Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000000732 arylene group Chemical group 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 3
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N Nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drugs Drugs 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- XMAYQACVLQZMQK-UHFFFAOYSA-N 2-[[4-[3-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]phenoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione Chemical compound O1C(=O)NC(=O)N1CC(C=C1)=CC=C1OC1=CC=CC(OC=2C=CC(CN3C(NC(=O)O3)=O)=CC=2)=C1 XMAYQACVLQZMQK-UHFFFAOYSA-N 0.000 claims 1
- LUACLLSCZRRTIH-UHFFFAOYSA-N 2-[[4-[4-[4-[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phenoxy]but-2-enoxy]phenyl]methyl]-1,2,4-oxadiazolidine-3,5-dione Chemical compound O1C(=O)NC(=O)N1CC(C=C1)=CC=C1OCC=CCOC(C=C1)=CC=C1CN1C(=O)NC(=O)O1 LUACLLSCZRRTIH-UHFFFAOYSA-N 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
Claims (11)
где одинаковые или отличаются друг от друга и каждый представляет собой фениленовую группу, которая может быть замещена, представляет I атом кислорода, группу, представленную формулой
группу, представленную формулой -S(O)n-, группу, представленную формулой -СО-, группу, представленную формулой
алкиленовую группу или алкениленовую группу, которая может соответственно прерываться атомом кислорода и/или атомом серы и которая может соответственно быть замещена, или группу, представленную формулой
R1 - означает атом водорода или низшую алкильную группу n: 0,1 или 2, R2 - атом водорода или низшая алкильная группа, L1 и L2 : одинаковые или отличаются друг от друга и каждый представляет атом кислорода, группу, представленную формулой
(R1 имеет указанные выше значения), группу, представленную формулой -S(O)n- (n имеет указанные выше значения), группу, представленную формулой -СО-, группу, представленную формулой
(R2 имеет указанные выше значения), или алкиленовую группу или алкениленовую группу, которая может соответственно прерываться атомом кислорода и/или атомом серы и которая может соответственно быть замещена, и циклоалкандиильная группа, ариленовая группа или пиридиндиильная группа, которая может соответственно быть замещена, или фармацевтически приемлемая соль его.1. Derived bisoxadiazolidinedione represented by the following General formula I
Where the same or different from each other and each represents a phenylene group that can be substituted, represents an oxygen atom I, a group represented by the formula
a group represented by the formula —S (O) n -, a group represented by the formula —CO—, a group represented by the formula
an alkylene group or an alkenylene group which can be interrupted by an oxygen atom and / or a sulfur atom and which can be substituted accordingly, or a group represented by the formula
R 1 - means a hydrogen atom or a lower alkyl group n: 0.1 or 2, R 2 - a hydrogen atom or a lower alkyl group, L 1 and L 2 : the same or different from each other and each represents an oxygen atom, a group represented by the formula
(R 1 is as defined above), a group represented by the formula —S (O) n - (n is as defined above), a group represented by the formula —CO—, a group represented by the formula
(R 2 is as defined above), either an alkylene group or an alkenylene group, which may be interrupted by an oxygen atom and / or a sulfur atom, respectively, and which may be substituted accordingly, and a cycloalkanediyl group, an arylene group or a pyridinediyl group which may be substituted accordingly, or a pharmaceutically acceptable salt thereof.
где L1 и L2 могут быть одинаковыми или отличающимися друг от друга и каждый представляет собой алкиленовую группу или алкениленовую группу, которая может соответственно прерываться атомом кислорода и/или атомом серы и которая может соответственно быть замещена одним или несколькими атомами галогена, и представляет собой циклоалкандиильную группу, ариленовую группу или пиридиндиильную группу, которая может соответственно быть замещена одним или несколькими заместителями, выбранными из группы, состоящей из атома галогена, низшей алкильной группы галоген низшей алкильной группы, низшей алкоксигруппы, цианогруппы, нитрогруппы, аминогруппы, низшей алкилзамещенной аминогруппы, карбамоильной группы и низшей алкилзамещенной карбамоильной группы.3. The compound according to claim 2, in which may be the same or different from each other and each represents a phenylene group which may be substituted by one or more substituents selected from the group consisting of a halogen atom, a lower alkyl group, and a halogen lower alkyl group, and L is 1) an alkylene group or an alkenylene group, which can be interrupted by an oxygen atom and / or a sulfur atom, respectively, and which can be substituted by one or more halogen atoms, or 2) by the group represented by the formula
where L 1 and L 2 may be the same or different from each other and each represents an alkylene group or an alkenylene group which may be interrupted by an oxygen atom and / or a sulfur atom and which may be substituted by one or more halogen atoms, respectively, and is a cycloalkanediyl group, an arylene group or a pyridinediyl group which may respectively be substituted with one or more substituents selected from the group consisting of a halogen atom, a lower alkyl group, halogen substituted lower alkyl group, lower alkoxy, cyano, nitro, amino, lower alkyl-substituted amino group , carbamoyl group and lower alkyl substituted carbamoyl group.
где одинковые или отличаются друг от друга и каждый представляет собой фениленовую группу, которая может быть замещена, L-представляет атом кислорода, группу, представленную формулой
группу, представленную формулой -S(O)n-, группу, представленную формулой -СО-, группу, представленную формулой
алкиленовую группу или алкениленовую группу, которая может соответственно прерываться атомом кислорода и/или атомом серы и которая может соответственно быть замещена, или группу, представленную формулой
R1 - атом водорода или низшая алкильная группа, n - 0, 1 или 2 , R2 - атом водорода или низшая алкильная группа, L1 и L2 - одинаковые или отличаются друг от друга и каждый представляет атом кислорода, группу, представленную формулой
(R1 имеет указанные выше значения), группу, представленную формулой -S(O)n- (n имеет указанные выше значения), группу, представленную формулой -СО-, группу, представленную формулой
(R2 имеет указанные выше значения), или алкиленовую группу или алкениленовую группу, которая может соответственно прерываться атомом кислорода и/или атомом серы и которая может соответственно быть замещена, и представляет циклоалкандиильную группу, ариленовую группу или пиридиндиильную группу, которая может соответственно быть замещена.
Where single or different from each other and each represents a phenylene group that can be substituted, L-represents an oxygen atom, a group represented by the formula
a group represented by the formula —S (O) n -, a group represented by the formula —CO—, a group represented by the formula
an alkylene group or an alkenylene group which can be interrupted by an oxygen atom and / or a sulfur atom and which can be substituted accordingly, or a group represented by the formula
R 1 is a hydrogen atom or a lower alkyl group, n is 0, 1 or 2, R 2 is a hydrogen atom or a lower alkyl group, L 1 and L 2 are the same or different from each other and each represents an oxygen atom, a group represented by the formula
(R 1 is as defined above), a group represented by the formula —S (O) n - (n is as defined above), a group represented by the formula —CO—, a group represented by the formula
(R 2 is as defined above), either an alkylene group or an alkenylene group, which may be interrupted by an oxygen atom and / or a sulfur atom, respectively, and which may be substituted accordingly, and represents a cycloalkanediyl group, an arylene group or a pyridinediyl group which may be substituted accordingly.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP12789893 | 1993-04-30 | ||
JPHEI-5-127898 | 1993-04-30 | ||
JP35020993 | 1993-12-29 | ||
JPHEI-5-350209 | 1993-12-29 | ||
PCT/JP1994/000696 WO1994025448A1 (en) | 1993-04-30 | 1994-04-26 | Novel bisoxadiazolidine derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
RU95122077A true RU95122077A (en) | 1997-09-20 |
RU2135487C1 RU2135487C1 (en) | 1999-08-27 |
Family
ID=26463731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU95122077A RU2135487C1 (en) | 1993-04-30 | 1994-04-26 | Bis-oxadiazolidinedione derivatives, pharmaceutical composition |
Country Status (14)
Country | Link |
---|---|
US (1) | US5643931A (en) |
EP (1) | EP0696585B1 (en) |
CN (1) | CN1045005C (en) |
AT (1) | ATE174593T1 (en) |
AU (1) | AU680496B2 (en) |
CA (1) | CA2160989A1 (en) |
DE (1) | DE69415314T2 (en) |
DK (1) | DK0696585T3 (en) |
ES (1) | ES2129123T3 (en) |
GR (1) | GR3029428T3 (en) |
HU (1) | HUT73431A (en) |
RU (1) | RU2135487C1 (en) |
TW (1) | TW401418B (en) |
WO (1) | WO1994025448A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU742388B2 (en) * | 1996-12-24 | 2002-01-03 | Chugai Seiyaku Kabushiki Kaisha | Aromatic amine derivatives having nos inhibiting action |
US6221914B1 (en) * | 1997-11-10 | 2001-04-24 | Array Biopharma Inc. | Sulfonamide bridging compounds that inhibit tryptase activity |
US6534037B1 (en) | 1998-01-21 | 2003-03-18 | Neorx Corporation | Non-steroidal compounds for steroid receptors and uses relating thereto |
ATE341343T1 (en) * | 2000-12-26 | 2006-10-15 | Sankyo Co | MEDICAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE IMPROVEMENT AGENT |
US20050119314A1 (en) * | 2002-04-05 | 2005-06-02 | Sankyo Company, Limited | Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent |
US7816385B2 (en) | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
JP2007508382A (en) * | 2003-10-14 | 2007-04-05 | イーライ リリー アンド カンパニー | Phenoxyether derivatives as PPAR modulators |
TW200815377A (en) | 2006-04-24 | 2008-04-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
TW200932219A (en) * | 2007-10-24 | 2009-08-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
EP2332528A1 (en) * | 2009-12-14 | 2011-06-15 | Grünenthal GmbH | Substituted aromatic dicarbonic acid amides as medicaments |
MY175797A (en) * | 2011-08-03 | 2020-07-09 | Univ Nat Taiwan | Agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4598153A (en) * | 1984-12-19 | 1986-07-01 | The United States Of America As Represented By The Department Of Health And Human Services | Metaphit, a specific acylating agent for the [3 H] phencyclidine |
AU645112B2 (en) * | 1990-08-23 | 1994-01-06 | Pfizer Inc. | Hypoglycemic hydroxyurea derivatives |
ES2157204T3 (en) * | 1991-04-17 | 2001-08-16 | Upjohn Co | DERIVATIVES OF (S) -3-PHENYLPIPERIDINE SUBSTITUTED, ITS PREPARATION AND USE AS DOPAMINE SELF-RECEPTOR ANTAGONISTS. |
DK0597102T3 (en) * | 1991-07-30 | 1999-08-09 | Yamanouchi Pharma Co Ltd | New bis-heterocyclic derivative and its salt and hypoglycemic composition |
US5420146A (en) * | 1994-05-10 | 1995-05-30 | American Home Products Corporation | Di-oxadiazolidine derivatives as antihyperglycemic agents |
JPH09303021A (en) * | 1996-05-17 | 1997-11-25 | Matsushita Electric Works Ltd | Proximity wireless electric lock control system |
-
1994
- 1994-04-26 ES ES94913821T patent/ES2129123T3/en not_active Expired - Lifetime
- 1994-04-26 AU AU65823/94A patent/AU680496B2/en not_active Ceased
- 1994-04-26 CA CA002160989A patent/CA2160989A1/en not_active Abandoned
- 1994-04-26 EP EP94913821A patent/EP0696585B1/en not_active Expired - Lifetime
- 1994-04-26 RU RU95122077A patent/RU2135487C1/en active
- 1994-04-26 CN CN94191963A patent/CN1045005C/en not_active Expired - Fee Related
- 1994-04-26 WO PCT/JP1994/000696 patent/WO1994025448A1/en active IP Right Grant
- 1994-04-26 HU HU9503090A patent/HUT73431A/en unknown
- 1994-04-26 US US08/537,907 patent/US5643931A/en not_active Expired - Fee Related
- 1994-04-26 DK DK94913821T patent/DK0696585T3/en active
- 1994-04-26 AT AT94913821T patent/ATE174593T1/en not_active IP Right Cessation
- 1994-04-26 DE DE69415314T patent/DE69415314T2/en not_active Expired - Fee Related
- 1994-04-28 TW TW083103862A patent/TW401418B/en not_active IP Right Cessation
-
1999
- 1999-02-17 GR GR990400511T patent/GR3029428T3/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU95122077A (en) | NEW DERIVATIVE BISOXADIAZOLIDINE | |
KR930701434A (en) | Oxazolidine Dione Derivatives | |
CA2166902A1 (en) | 3-amidopyrazole derivatives, process for preparing these and pharmaceutical compositions containing them | |
KR890008108A (en) | Imidazoline | |
HK1028348A1 (en) | Novel heterocyclic analogs of diphenylethylene compounds | |
KR960704546A (en) | Use of Thiazolidinedione Derivatives and Related Antihyperglycemic Agents in the Treatment of Disease States at Risk for Progressing to Noninsulin-Dependent Diabetes Mellitus ) | |
KR930702287A (en) | New compound | |
KR910016742A (en) | Alkylated oxo-piperazinyl-triazine | |
KR900009611A (en) | Pyrimidine derivatives, preparation methods thereof, herbicides containing the same and compositions of herbicides containing the same together with other active ingredients | |
RU92016545A (en) | HETEROCYCLIC COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION | |
IE43624L (en) | Amidoximes. | |
KR937000469A (en) | Thiazolidine-2,4-dione derivatives, salts thereof, and preparation methods thereof | |
ES8102090A1 (en) | Omega-(2-(N-lower alkyl-benzamido)-phenyl)-alkanoic acids, their use and preparation, and medicaments containing them. | |
KR890001988A (en) | Substituted alkencarboxylic acid amides and derivatives thereof | |
KR970707122A (en) | QUINOLINE DERIVATIVE | |
EA200200470A1 (en) | NEW TIAZOLIDINDION DERIVATIVES AS ANTI-DIABETIC MEANS | |
EP0270093A3 (en) | Lactam derivatives, processes for the preparation thereof, pharmaceutical compositions comprising the same, and the use of such derivatives for the manufacture of a medicament having valuable therapeutic properties | |
ATE32894T1 (en) | THIOMETHYLPYRIDIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS. | |
KR930009999A (en) | Butyric acid derivative and pesticide composition containing the same | |
KR880002828A (en) | Dihydropyridine derivatives and pharmaceutical compositions thereof | |
RU97111807A (en) | THIAZOLIDININE DERIVATIVES AND THE THERAPEUTIC DRUG OR PREVENTIVE DRUG AGAINST PREFABRICATED TOAD CONTAINING DERIVATIVES AS AN ACTIVE INGREDIENT | |
KR830009069A (en) | Method for preparing alkanolamine derivatives | |
KR890008121A (en) | Rhodanine Derivatives and Pharmaceutical Compositions | |
KR920006337A (en) | Heteroaryl methyl benzene | |
JPS6429369A (en) | Oxazoline derivative |